Syros Pharmaceuticals Inc

NASDAQ:SYRSUnited States

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

Contact Information

Headquarters

35 Cambridge Park DriveCAMBRIDGE, MA, United States 02140

Phone

617-744-1340

Fax

617-744-1377

Executives

Independent Chairman of the Board

Peter Wirth

President, Chief Executive Officer, Director

Gerald Quirk

Chief Development Officer

Kristin Stephens

Director

Nancy Simonian

Independent Director

Marsha Fanucci